Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Janssen Says Guselkumab Psoriatic Arthritis Studies Meet Endpoints

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2019 | 08:22am EDT

By Michael Dabaie

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said the Phase 3 Discover 1 and 2 studies, which evaluated guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis, met their primary endpoints.

The studies met the goal of American College of Rheumatology 20% improvement, and the safety profiles observed for guselkumab in the program were consistent with previous studies of guselkumab and current prescribing information, Janssen said.

Data from the two studies will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of guselkumab as a treatment for psoriatic arthritis, which are anticipated for later this year.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/19JOHNSON & JOHNSON : Congo to use second vaccine to fight Ebola
AQ
08/16JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
08/16JOHNSON & JOHNSON : Ebola Crisis-The Vaccines Debate
AQ
08/15JOHNSON & JOHNSON : Janssen Announces European Commission Approval of Imbruvica ..
AQ
08/13JOHNSON & JOHNSON : J&J's Janssen Gets EC OK for Expanded Use of Imbruvica
DJ
08/12JOHNSON & JOHNSON : Thinking about trading options or stock in AbbVie, Bristol-M..
PR
08/12JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTURO ..
AQ
08/09JOHNSON & JOHNSON : Janssen Announces U.S. FDA Accelerated Approval for SIRTUROÒ..
PU
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
08/09WHAT IS THE KEY OUTCOMES ANALYSIS OF : Pfizer, Amgen, Novartis, Bayer, Johnson &..
AQ
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 116 M
Yield 2019 2,84%
P/E ratio 2019 19,7x
P/E ratio 2020 17,4x
EV / Sales2019 4,35x
EV / Sales2020 4,08x
Capitalization 349 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 148,50  $
Last Close Price 132,25  $
Spread / Highest target 27,8%
Spread / Average Target 12,3%
Spread / Lowest Target -6,24%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.48%349 030
ROCHE HOLDING LTD.12.24%238 299
MERCK AND COMPANY12.80%217 785
NOVARTIS17.81%204 677
PFIZER-19.40%191 651
NOVO NORDISK AS16.65%122 509